Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (164)	1/1/2002 1:58:15 PM
From: keokalani'nui	Respond to of 897

Yes. Two challenges. In my view, the one that matters (and is unlikely to be settled by license) is the IMCL patent covering any EGFr Mab treatment combined with anti-neoplastic agents. This will be challenged by abgx/amgn, some also think it could be by DNA but the DNA EGFr patent can be read to be limited to the Herceptin receptor. One of the the Wasksals suggested to the markets that DNA has no problem with the imcl EGFr patent, but is it time reconsider the source? The recently issued DNA antibody patent may be involved now also, I don't really know, but if so it can likely be licensed. I am not the guy to give an opinion on any of this, but there are some crackerjack biofreaks who see imcl patent position as vulnerable. Since it is conceivable this BLA could be put back on track with a 'mere' 6-month delay, be careful with the short. Go for the deep out of the money puts. If they refile in 8 weeks with acceptance for review, it could be back in the 60s quick. Wilder

To: tuck who wrote (164)	1/3/2002 4:16:30 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 897

Disease Sciences is at it again, especially with last sentence: >>Press Release SOURCE: Disease Sciences, Inc. Disease Sciences Announces 1 for 10 Reverse Split BOCA RATON, Fla.--(BUSINESS WIRE)--Jan. 3, 2002--Disease Sciences, Inc. (OTC BB: DISE) announced today that it has declared a one for ten reverse stock split of its common stock, to be effective at the opening of trading on Monday, January 7, 2002. As a result of the reverse stock split, each ten shares of previously outstanding common stock will become one post-split share of common stock. Stockholders are not required to tender their existing certificates for shares, but may do so if they desire. The new cusip number for the post-split shares of common stock will be 25469Y 20 5, and the new trading symbol for the common stock will be ``DSSC''. The number of common shares the company is authorized to issue, and the par value per share of the Company's common stock will not be effected by the reverse split. Dr. Wayne Goldstein Disease Sciences CEO, stated, ``The re-capitalization of Disease Sciences is important to our future as it will allow the Company to expedite further funding to pay for its drug development program. Additionally, the re-capitalization may significantly enhance the possibility for the company to be acquired or to acquire other companies based upon its new structure.'' <<